Business context and reporting period
The filing identifies the registrant as MEDNAX, Inc.; the supplied metadata names Pediatrix Medical Group, Inc. This is MEDNAX’s unaudited Form 10-Q for the quarter and nine months ended September 30, 2017. MEDNAX provides physician services including neonatology, anesthesia, radiology, maternal-fetal medicine and pediatric specialties, as well as teleradiology and related services.
Financial performance and liquidity
Amounts below are in millions of dollars except per-share data and margins.
| Metric | Q3 2017 | Q3 2016 | Nine months 2017 | Nine months 2016 |
|---|---|---|---|---|
| Revenue | $869.0 | $828.0 | $2,547.5 | $2,352.4 |
| Operating income | $126.4 | $156.9 | $354.4 | $428.9 |
| Operating margin | 14.6% | 18.9% | 13.9% | 18.2% |
| Net income attributable to MEDNAX | $65.9 | $96.5 | $184.3 | $246.8 |
| Diluted EPS | $0.71 | $1.04 | $1.98 | $2.65 |
| EBITDA (non-GAAP) | $151.5 | $181.2 | $430.8 | $493.2 |
| Adjusted diluted EPS (non-GAAP) | $0.87 | $1.09 | $2.47 | $2.99 |
For the nine months, operating cash flow was $315.7 million versus $312.8 million in 2016; investing cash outflow was $387.5 million, mainly for acquisitions, and financing cash inflow was $64.4 million. Cash and cash equivalents were $48.4 million at September 30, 2017, and working capital was $177.3 million. Days sales outstanding were 55.1 days, versus 54.9 at year-end 2016.
At September 30, the company reported $919.0 million drawn on its revolving credit line and $878.2 million of long-term debt and capital lease obligations, plus $29.3 million current debt and lease obligations. Separately, it had $750 million principal amount of 5.25% senior notes due 2023. The filing states that $780.6 million remained available under the then-current credit agreement. Management said cash, operating funds and credit availability were expected to cover working capital, anticipated acquisitions and capital spending, repurchases and contractual obligations for at least 12 months.
Material changes versus the prior comparable period
- Q3 revenue increased 4.9%, but operating income fell 19.4%; nine-month revenue rose 8.3%, while operating income declined 17.4%.
- Acquisitions drove revenue growth: $35.0 million of Q3 growth came from acquisitions; for the nine months, acquisition revenue added $202.7 million, more than offsetting a $7.6 million decline in same-unit revenue.
- Same-unit revenue increased 0.7% in Q3, with reimbursement-related gains offset partly by lower volumes. It declined 0.3% for the nine-month period, principally from lower patient volumes across most service lines.
- Practice salaries and benefits rose 12.4% in Q3 and 14.8% for the nine months, outpacing revenue growth. Management attributed this to acquisition-related staffing, existing-unit growth and faster clinician compensation increases.
- Operating margin contracted 440 basis points in Q3 and 432 basis points for the nine months, reflecting higher operating costs and weaker same-unit revenue. Interest expense also increased, associated with higher borrowing rates and debt levels.
- 2016 comparisons include a $10.6 million favorable tax benefit from settlement of a tax matter. Adjusted EPS excludes this item, as well as amortization and stock-based compensation.
Outlook, risks and unusual items
- No quantified earnings or revenue guidance is provided. Management anticipated continued faster growth in clinician compensation expense and said payor-mix shifts in anesthesiology had prompted review of acquisition terms, creating uncertainty about timing.
- MEDNAX completed nine physician-practice acquisitions in the first nine months for total consideration of $356.6 million, primarily cash. Goodwill increased, and approximately $46 million of acquired long-lived assets was classified as held for sale pending a potential contribution to a joint venture.
- On October 30, 2017, after quarter-end, the company replaced its credit agreement with a $2.0 billion unsecured revolving facility maturing October 31, 2022; the facility may be increased to $2.4 billion subject to conditions. It includes leverage and interest coverage covenants and restrictions on distributions.
- Key exposures include shifts toward lower-reimbursement government healthcare programs, patient inability to pay, healthcare policy changes, Medicare payment rules, clinician compensation costs, acquisition execution, and interest-rate changes. A 1 percentage-point rate change on September 30 variable-rate borrowings was estimated to affect annual pretax income by about $10.8 million.
- Professional liability is partly self-insured. The company reported $240.5 million of professional liability exposure, including $37.3 million in accrued expenses, and a $14.0 million related insurance receivable. Government audits and malpractice claims may have material effects; outcomes and potential audit liabilities were not determinable with clarity.
- The company reported no material change to previously disclosed risk factors and concluded disclosure controls were effective. It also stated that it was in material compliance with debt covenants at quarter-end.
Most important facts for investors to verify
- Confirm the registrant identity and relationship, if any, between the MEDNAX filing and the Pediatrix Medical Group named in the request metadata.
- Track same-unit volumes and reimbursement trends, especially anesthesiology and government-program payer mix.
- Assess whether revenue growth from acquisitions can offset clinician compensation and other operating-cost pressures and stabilize margins.
- Review leverage, available borrowing capacity, covenant headroom and the terms of the post-quarter credit facility.
- Monitor professional liability reserves, insurance recoveries and the possible financial impact of government inquiries or litigation.